osimertinib + palbociclib

Osimertinib + palbociclib is an investigational combination therapy consisting of two small molecule drugs: osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Osimertinib selectively targets mutant forms of EGFR commonly found in non-small cell lung cancer (NSCLC), including T790M, L858R, and exon 19 deletions. Palbociclib inhibits CDK4/6 activity to block cell cycle progression from G1 to S phase by preventing phosphorylation of the retinoblastoma protein. The combination has been studied preclinically and in case reports for overcoming acquired resistance to EGFR-TKI therapy in NSCLC with specific molecular aberrations such as CDK4 amplification or PIK3CA mutation. This dual approach aims to synergistically arrest tumor cell proliferation by targeting both oncogenic signaling and cell cycle regulation[1][2][7][8].

Brand names

Tagrisso (osimertinib)Ibrance (palbociclib)

Other names

osimertinib + palbociclib